A Study Of Relatlimab Plus Nivolumab In Combination With Chemotherapy Vs. Nivolumab In Combination With Chemotherapy In Participants With Stage IV Or Recurrent NSCLC Read more
A Randomized Phase 3 Study Of Sitravatinib In Combination With Nivolumab Versus Docetaxel In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On Or After Platinum-Based Chemotherapy In Combination With Checkpoint Inhibitor Therapy Read more
Phase IV Observational Study To Collect Safety And Outcome Data In Real-World Setting In Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca (EMERGE 402) Read more
A Phase 2 Randomized, Double-Blind, Clinical Trial Of Trilaciclib Versus Placebo In Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel In The 2nd/3rd Line Setting (PRESERVE 4) Read more
A Phase 1 Trial To Evaluate The Potential Impact Of Renal Impairment On The Pharmacokinetics And Safety Of CPX-351 (Daunorubicin And Cytarabine) Liposome For Injection Treatment In Adult Patients With Hematologic Malignancies Read more
Abbvie, Protocol: M16-191, PI: Dr. Mccloskey, Title A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1) Read more
Abbvie, Protocol: M20-178, PI: Dr. Mccloskey, A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy And Safety Of Navitoclax In Combination With Ruxolitinib Versus Best Available Therapy In Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) Read more
A Multi-Phase, Dose-Escalation Followed By An Open-Label, Randomized, Crossover Study Of Oral ASTX030 (Cedazuridine And Azacitidine Given In Combination) Versus Subcutaneous Azacitidine In Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Or Acute Myeloid Leukemia (AML) Read more
An Open-Label, Multicenter, Extension Study For Subjects Who Participated In Prior Clinical Studies Of ASTX727 (Standard Dose) Read more
